How much supervision is necessary for women taking mifepristone and misoprostol for early medical abortion?

Women's Health

Volumn 4, Issue 2, 2008, Pages 107-111

  Shannon, Caitlin ^a   Winikoff, Beverly ^b  

^a GYNUITY HEALTH PROJECTS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIPYRETIC AGENT; MIFEPRISTONE; MISOPROSTOL;

BLEEDING; CHILL; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG UTILIZATION; ECHOGRAPHY; ECTOPIC PREGNANCY; EDITORIAL; FEVER; GESTATIONAL AGE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HUMAN; INFECTION; MEDICAL ABORTION; MEDICAL PRACTICE; PATIENT ATTITUDE; PRESCRIPTION; SPONTANEOUS ABORTION; WOMEN'S HEALTH;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; GESTATIONAL AGE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; TREATMENT OUTCOME;

EID: 41949140945     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.2.107     Document Type: Editorial

References (35)

1. Jones RK, Henshaw SK: Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect. Sex. Reprod. Health 34(3), 154-161 (2002).
2. Howie FL, Henshaw RC, Naji SA, Russell IT, Templeton AA: Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial. Br. J. Obstet. Gynaec. 104(7), 829-833 (1997).
3. American College of Obstetricians and Gynecologists Committee on Practice Bulletins Gynecology: ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Medical management of abortion. Obstet. Gynecol. 97, 1-13 (2001).
4. National Abortion Federation: early medical abortion with mifepristone and other agents. National Abortion Federation, Washington, DC, USA (2002).
5. Royal College of Obstetricians and Gynaecologists: the care of women requesting induced abortion. RCOG Press, London, UK (2001).
6. Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH: Induced abortion: estimated rates and trends worldwide. Lancet 370(9595), 1338-1345 (2007).
7. Henderson JT, Hwang AC, Harper CC, Steward FH: Safety of mifepristone abortions in clinical use. Contraception 72(3), 175-178 (2005).
8. Hausknecht R: Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. Contraception 67(6), 463-465 (2003).
9. Kruse B, Poppema S, Creinin MD, Paul M: Management of side effects and complications in medical abortion. Am. J. Obstet. Gynecol. 183(Suppl. 2), S65-S75 (2000).
10. Savitz DA, Terry JW Jr, Dole N, Thorp JM Jr, Siega-Riz AM, Herring AH: Comparison of pregnancy dating by last menstrual period, ultrasound scanning, and their combination. Am. J. Obstet. Gynecol. 187, 1660-1666 (2002).
11. Blanchard K, Cooper D, Dickson K et al.: A comparison of women's, providers' and ultrasound assessments of pregnancy duration among terminatien of pregnancy clients in South Africa. BJOG 114(5), 569-575 (2007).
12. Ellertson C, Elul B, Ambardekar S, Wood L, Carroll J, Coyaji K: Accuracy of assessment of pregnancy duration by women seeking early abortions. Lancet 355(9207), 877-881 (2000).
13. Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases. Contraception 71(5), 327-332 (2005).
14. Ashok PW, Kidd A, Flett GM, Fitzmaurice A, Graham W, Templeton A: A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. Hum. Reprod. 17(1), 92-98 (2002).
15. FDA: Mifeprexe®. Washington, DC, USA: (2005).
16. Ngoc NT, Nhan VQ, Blum J, Mai TT, Durocher JM, Winikoff B: Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. BJOG 111(8), 814-819 (2004).
17. Hamoda H, Ashok PW, Flett GM, Templeton A: Home self-administration of misoprostol for medical abortion up to 56 days' gestation. J. Fam. Plann. Reprod Health Care 31(3), 189-192 (2005).
18. Guengant JP, Bangou J, Elul B, Eilertson C: Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe. Contraception 60(3), 167-172 (1999).
19. Shannon C, Wiebe E, Jacot F et al.: Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. BJOG 113(6), 621-628 (2006).
20. Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B: Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. Eur. J. Contracept, Reprod. Health Care 10(3), 184-191 (2005).
21. WHO Research Group on Post-ovulatory Methods for Fertility Regulation: WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. BJOG 110, 808-818 (2003).
22. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BJOG 107(4), 524-530 (2000).
23. Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA; MOD Study Trial Group: A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet. Gynecal 103(5 Pt 1). 851-859 (2004).
24. Schaff EA, Fielding SL, Westhoff C et al.: Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 284(15), 1948-1953 (2000). Erratum in: JAMA 22-29: 284(20), 2597 (2000).
25. Guest J, Chien P, Thomson M, Kosseinn ML: Randomised controlled trial comparing efficacy of same day administration of milepristone and misoprostol for termination of pregnancy with the standard 36-to 48-hour protocol. BJOG 112 (10), 1457 (2005).
26. Spitz IM, Bardin CW, Benton L, Robbins A: Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med. 338, 1241-1247 (1998).
27. Fischer M, Bhatnagar J, Guarner J et al.: Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion N. Engl. J. Med. 353(22), 2352-2360 (2005).
28. Sinave C, Le Templier G, Blouin D, Leveille F. Deland E: Toxic shock syndrome due to Clostridium sordellii. a dramatic postpartum and postabortion disease. Clin. Infect. Dis. 35(11), 1441-1443 (2002).
29. Cohen AL, Bhatnagar I Reagan S et al.: Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet, Gynecol. 110(5), 1027-1033 (2007).
30. Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JP: Expectant, medical, or surgical management of first-trimester miscarriage: a meta-analysis. Obstet Gynecol. 105(5 Pt 1). 1104-1113 (2005).
31. Blum J, Winikoff B, Gamzell-Danielsson K, Ho PC, Schiavon R, Weeks A: Treatment of incomplete abortion and miscarriage with misoprostol. Int. J Gynaecol. Obstet. 99(Suppl. 2), S186-S189 (2007).
32. Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM: National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial: a comparison of medical management with misoprostol and surgical management for early pregnancy failure. N. Engl. J. Med. 353(8), 761-769 (2005).
33. Philip N, Shannon C, Winikoff B (Eds).: Misoprostol and Teratology: Reviewing the Evidence. New York Population Council, NY, USA (2002).
34. Orioli IM, Castilla EE: Epidemiological assessment of misoprostol teratogenicity. Br. J. Obstet Gynaecol., 107(4), 519-523 (2000).
35. Castilla EE, Orioli IM: Teratogenicity of misoprostol: data from the Latin-American Collaborative Study of Congenital Malformations (ECLAMC). Am. J. Med. Genet. 51(2), 161-162 (1994).